RT Journal Article
SR Electronic
T1 Comprehensive Study of Germline Mutations and Double-Hit Events in Esophageal Squamous Cell Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.04.21251116
DO 10.1101/2021.02.04.21251116
A1 Zeng, Bing
A1 Huang, Peide
A1 Du, Peina
A1 Sun, Xiaohui
A1 Huang, Xuanlin
A1 Fang, Xiaodong
A1 Li, Lin
YR 2021
UL http://medrxiv.org/content/early/2021/02/06/2021.02.04.21251116.abstract
AB Esophageal squamous cell cancer (ESCC) is the eighth most common cancer around the world. Several reports have focused on somatic mutations and common germline mutations in ESCC. However, the contributions of pathogenic germline alterations in cancer susceptibility genes (CSGs), highly frequently mutated CSGs, and pathogenically mutated CSG-related pathways in ESCC remain unclear. We obtained data on 571 ESCC cases from public databases and East Asian from the 1000 Genomes Project database and the China Metabolic Analytics Project database to characterize pathogenic mutations. We detected 157 mutations in 75 CSGs, accounting for 25.0% (143/571) of ESCC cases. Six genes had more than five mutations: TP53 (n = 15 mutations), GJB2 (n = 8), BRCA2 (n = 6), RECQL4 (n = 6), MUTYH (n = 6), and PMS2 (n = 5). Our results identified significant differences in pathogenic germline mutations of TP53, BRCA2, and RECQL4 between the ESCC and control cohorts. Moreover, we identified 84 double-hit events (16 germline/somatic double-hit events and 68 somatic/somatic double-hit events) occurring in 18 tumor suppressor genes from 83 patients. Patients who had ESCC with germline/somatic double-hit events were diagnosed at younger ages than patients with the somatic/somatic double-hit events, although the correlation was not significant. Fanconi anemia was the most enriched pathway of pathogenically mutated CSGs, and it appeared to be a primary pathway for ESCC predisposition. The results of this study identified the underlying roles that pathogenic germline mutations in CSGs play in ESCC pathogenesis; increased our awareness about the genetic basis of ESCC; and provided suggestions for using highly mutated CSGs and double-hit features in the early discovery, prevention, and genetic counseling of ESCC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the institutional review board of the Beijing Genomics InstitutionAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data of this project can be found in the Sequence Read Archive hosted by the National Center for Biotechnology Information under accession numbers PRJNA315775, PRJNA399748, PRJNA401209, PRJNA230271, PRJNA317404, SRA112617 and SRP034680 and in the European Genome-Phenome Archive under accession number EGAD00001000845.The whole-exome sequencing data of esophageal squamous cell cancer samples from The Cancer Genome Atlas are available from the National Cancer Institute Genomic Data Commons (https://portal.gdc.cancer.gov/). All relevant datasets for this study are available from the authors.